INIS
patients
100%
antibodies
86%
anticoagulants
75%
thrombin
72%
comparative evaluations
66%
reviews
57%
covid-19
55%
proteins
51%
evaluation
50%
performance
48%
women
47%
levels
46%
laboratories
38%
vaccines
37%
control
36%
risks
35%
testing
34%
values
34%
viruses
32%
doses
30%
administration
30%
populations
29%
plasma
29%
diseases
26%
sensitivity
26%
messenger-rna
26%
estrogens
24%
antigens
24%
coronaviruses
22%
concentration
22%
information
20%
data
19%
immunity
19%
capacity
18%
mutations
18%
receptors
17%
assessments
16%
biological markers
16%
workers
15%
prothrombin
14%
thrombosis
14%
in vitro
14%
interventions
13%
kinetics
13%
range
13%
hormones
13%
emergencies
13%
detection
12%
nucleosomes
12%
peaks
12%
men
12%
neutrophils
12%
mortality
12%
geometry
11%
thromboplastin
11%
cytokines
10%
liquids
10%
algorithms
10%
humans
10%
chemistry
10%
lungs
10%
biopsy
10%
dexamethasone
10%
influenza
10%
dimers
10%
durability
10%
lipids
10%
metabolism
10%
lupus
10%
transplants
10%
ablation
10%
accuracy
10%
wave forms
10%
glioblastomas
10%
medicine
10%
bones
10%
screening
10%
symptoms
10%
speed
9%
production
8%
therapy
8%
genetics
8%
sex
8%
histones
8%
inflammation
8%
carbohydrates
8%
mass spectrometry
6%
inhibition
6%
venoms
6%
adults
6%
investigations
5%
globulins
5%
blood
5%
traps
5%
endometrium
5%
prophylaxis
5%
reduction
5%
vitamin k
5%
Keyphrases
Bivalent Boosters
21%
Breakthrough Infection
14%
XBB.1.5
14%
Subvariant
12%
SARS-CoV-2 Omicron
10%
Cytokine Response
10%
Clinical Performance Evaluation
10%
Rapid Antigen
10%
Pseudotyped Virus
10%
SARS-CoV-2 Neutralizing Antibody
10%
Measurement Analysis
10%
Breakthrough Cases
10%
Moderna mRNA-1273
10%
Atrial Fibrillation Ablation
10%
Randomized Double-blind Study
10%
Liquid Biopsy
10%
Panel Review
10%
D-dimer Assay
10%
ChAdOx1 nCoV-19
10%
Bone Turnover
10%
Clinical Chemistry
10%
COVID-19 Breakthrough Infections
10%
Strip Test
10%
Diagnostic Test Accuracy
10%
N Antigen
10%
Anticoagulant Effect
10%
Rivaroxaban
10%
Neutralizing Antibodies
10%
In Vitro Study
10%
BNT162b2
10%
Literature Review Analysis
10%
AZD7442
10%
Cilgavimab
10%
Tixagevimab
10%
Geometric Mean Titer
10%
Omicron Variant
7%
Factor V Leiden mutation
7%
Anti-RBD IgG
6%
D614G
6%
Virus Entry
5%
Angiotensin-converting Enzyme 2 Receptor
5%
SARS-CoV-2 Pseudovirus
5%
Biosafety Level 3
5%
Laboratory Staff
5%
Normalized Ratio
5%
User Satisfaction
5%
High Users
5%